| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PLX4720 | CCLE | pan-cancer | AAC | 0.3 | 5e-09 |
| mRNA | PD-0325901 | CCLE | pan-cancer | AAC | 0.21 | 4e-05 |
| mRNA | AZD6244 | CCLE | pan-cancer | AAC | 0.16 | 0.002 |
| mRNA | RAF265 | CCLE | pan-cancer | AAC | 0.11 | 0.06 |
| mRNA | TAE684 | CCLE | pan-cancer | AAC | -0.1 | 0.07 |
| mRNA | Topotecan | CCLE | pan-cancer | AAC | -0.087 | 0.09 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | -0.086 | 0.1 |
| mRNA | PD-0332991 | CCLE | pan-cancer | AAC | -0.089 | 0.1 |
| mRNA | Irinotecan | CCLE | pan-cancer | AAC | -0.1 | 0.1 |
| mRNA | Nilotinib | CCLE | pan-cancer | AAC | -0.091 | 0.1 |